MONROVIA, Calif. and HANGZHOU, China, Nov. 13 Niusule Biotech Corp. ("Niusule" or the "Company") (OTC Bulletin Board: NIUS), a leading U.S.-based biotech company focused on developing and selling nutritional products for children, today announced that Mr. Ping (Vince) Huang was named the Company's chief financial officer on November 6, 2009. Previously, Ms. Qinghua Hu, the Company's chief executive officer, also served as Niusule's CFO. The Company also retained Mr. Pei Pei as chief marketing officer of Niusule Bioengineering (Hangzhou) Co. Ltd. (Niusule Bioengineering), the Company's subsidiary in China.
Mr. Huang's work experience includes key positions in investment banking, consulting, and business development. He most recently served as an investment consultant for PIEPS, an affiliate of Gemstong Capital, where he initiated and managed qualitative and quantitative analysis for buyout execution. Mr. Huang also worked on the University of Alabama-Birmingham's life-science entrepreneurship program, where he was responsible for analysis and market research related to the commercialization of intellectual property. Prior to that, Mr. Huang was a business analyst for Beijing Kawin Biotech Co., Ltd., coordinating regulatory approvals for manufacturing and control processes. He holds a Bachelor of Engineering degree with a major in Biopharmaceuticals from China Pharmaceutical University and a Masters of Business Administration specializing in Finance from the UCLA Anderson School of Management. Mr. Huang has a Ph.D. in Pharmacology and Toxicology from the University of Alabama, Birmingham. He is fluent in English and Mandarin.
Mr. Pei has a strong marketing background in the Pharmaceutical and Bioengineering industry. Prior to joining Niusule, he served as Marketing Manager of Zhejiang at Shanghai Longbin Biotechnology Co., Ltd. He also worked as Manager of Zhejiang Branch, at Beijing Sinceretime Pharmaceutical Company and as Sales Director of Shanghai Asia Pioneer Pharmaceutical Co.,
Ltd. Mr. Pei has a college degree from China University of Geosciences.
"We would like to welcome Mr. Huang and Mr. Pei on board. We look forward to working with them and believe they will make meaningful contributions to Niusule. Mr. Huang's solid financial background will enhance our corporate finance, financial reporting and internal controls. I am also pleased that Mr. Pei with his extensive marketing experience will be leading our aggressive market expansion strategy and assisting Niusule to achieve its goals," commented Ms. Qinghua Hu, CEO of Niusule Biotech Corp. "I am delighted that with these additions, I can now focus my full attention on business strategy and planning our future growth and development," added Ms. Hu.
About Niusule Biotech Corp.
Niusule Biotech Corp. ("Niusule" or "the Company"), through its wholly owned subsidiary Niusule Bioengineering (Hangzhou) Co. Ltd., markets and distributes health food and related products manufactured in the US to Chinese consumers. The Company launched its Niusule Gummy Bears nutritional supplements for children in September 2009 and its PlantFusion protein powder in July 2009. Niusule currently has a retail distribution network comprised of 36 outlets at high-end supermarkets and shopping malls in Zhejiang province and is aggressively seeking to expand into other regions in China. Niusule was founded in April 2008 and is headquartered in Monrovia, California. For more information, contact CCG Investor Relations directly or go to Niusule's website at http://www.niusule.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such factors or to announce publicly the results of any revisions of the forward-looking statements contained herein to reflect future events or developments. You are urged to consider these factors care in evaluating the forward-looking statements herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.
Contact: Jeff Tsang Niusule Biotech Corp. (626) 446-4688 Email: [email protected]
Website: www.niusule.com Mabel Zhang CCG Investor Relations (310) 954-1353 [email protected]
SOURCE Niusule Biotech Corp.